Intermittent theta-burst stimulation, or iTBS, can deliver a depression treatment session in about three minutes, compared with roughly 37 minutes for the traditional protocol studied in the THREE-D trial. Accelerated TMS changes the schedule by delivering multiple sessions per day; the Stanford Neuromodulation Therapy trial studied a specific MRI-targeted approach, not simply a shorter appointment.
For someone comparing New Jersey providers, the important questions are what treatment is actually being offered, how closely it matches a studied protocol, and whether a prescriber considers it appropriate. A short stimulation session and an accelerated course are different features.
Theta burst and traditional TMS: what changes?
Transcranial magnetic stimulation uses a coil placed against the scalp to deliver magnetic pulses to a selected brain region. Treatment does not involve surgery, and patients generally remain awake during stimulation.
Traditional repetitive TMS and iTBS differ in how those pulses are organized. Theta burst groups pulses into brief bursts; “intermittent” means that stimulation alternates with pauses. The pattern allows the studied iTBS session to be much shorter than the conventional comparison session.
In the THREE-D randomized non-inferiority trial, investigators compared three-minute iTBS with 37.5-minute, 10 Hz repetitive TMS in patients with depression. The study found iTBS non-inferior to the conventional treatment, with comparable efficacy and tolerability.
“Non-inferior” means the shorter treatment met the study’s predefined standard for not being unacceptably worse than the comparator. It does not mean every patient responded equally to both treatments, or that either treatment guarantees improvement.
The finding supports the particular comparison studied. It does not establish that every theta-burst schedule, stimulation dose, or accelerated package will have the same results.
Stimulation time is not total appointment time
The three-minute figure refers to stimulation time in the THREE-D protocol, not necessarily the full time you spend at a clinic. Check-in, positioning, symptom review, and equipment setup also take time. Initial assessment and treatment planning are separate parts of care.
Ask the provider to distinguish:
- Time spent receiving stimulation.
- Total appointment length, including setup.
- Time between sessions if several are scheduled that day.
- Total time required across the planned course and follow-up.
This distinction matters if you are traveling from Jersey City or coordinating appointments around work in Princeton. A brief session may still require substantial travel. An accelerated schedule may reduce separate travel days while requiring you to remain near the clinic for much of the day.
Ask for a sample daily schedule before making transportation, caregiving, or work arrangements.
What makes TMS accelerated?
“Accelerated” describes how treatment sessions are grouped over time. It is not another name for theta burst. A clinic can use a short iTBS session without offering the Stanford protocol, and an accelerated service should be evaluated by its actual treatment plan rather than its marketing label.
Ask what stimulation pattern is used, how sessions are spaced, how the target is selected, and how the overall dose is determined. These details help your prescriber understand whether the proposed treatment resembles the research cited by the clinic.
The Stanford randomized trial evaluated an accelerated, MRI-targeted iTBS protocol delivered over five days. Its findings should not be treated as evidence for all services described as “accelerated TMS.”
What the Stanford protocol involves
Stanford Neuromodulation Therapy, abbreviated SNT, combines accelerated iTBS with MRI-based targeting. Rather than merely shortening each visit, the studied approach brought together imaging-based target selection and a concentrated treatment schedule.
In the double-blind, sham-controlled SNT trial, 29 patients participated in an accelerated treatment study conducted over five days. At four weeks, the active-treatment group had a mean 52.5% reduction in scores on the Montgomery–Åsberg Depression Rating Scale, or MADRS, compared with 11.1% in the sham group.
Those percentages describe average changes in symptom scores. They are not the percentages of patients who recovered, and they do not predict an individual patient’s chance of remission.
The trial provides controlled evidence for the studied protocol, but its small sample limits how confidently its results can be generalized. The reported follow-up result also does not establish how long any individual’s improvement will last.
If a clinic uses terms such as “Stanford-style” or “SNT-inspired,” ask what those terms mean. A resemblance in scheduling does not establish that the clinic uses the same targeting method or treatment parameters.
FDA-cleared and off-label are different questions
Research evidence and FDA clearance are not interchangeable. A published trial is not, by itself, proof that the exact device, protocol, and intended use offered by a clinic are FDA-cleared.
A clinic should distinguish an FDA-cleared use from an off-label use explicitly. FDA-cleared use means treatment falls within the relevant device’s cleared labeling; off-label use falls outside that labeling. Neither label guarantees a particular outcome.
The studies discussed here provide evidence about depression treatment under their respective protocols. They should not be used to imply FDA clearance for another condition or a modified schedule.
Ask the prescriber:
- Is the exact treatment being proposed for my diagnosis an FDA-cleared use or an off-label use?
- Which device and labeling support that answer?
- Does your proposed schedule fall within that labeling?
- If any part is off-label, what is the rationale, supporting evidence, and uncertainty?
An off-label proposal deserves a clear discussion, not an assumption that it is either equivalent to a cleared use or automatically inappropriate.
How to judge whether a clinic is a good fit
Start with the clinical evaluation, not the promise of speed. A consultation should review your diagnosis, previous treatments, current medications, relevant medical history, and goals. TMS screening also includes questions about seizure history and implanted metal or electronic devices.
For background before that conversation, explore our information about TMS for depression. The prescriber should explain how your history relates to the proposed treatment and discuss alternatives without promising a response.
When comparing services in our New Jersey TMS provider directory, look for clear answers in these areas:
- Protocol: What exactly will be delivered, and how does it compare with the study the clinic cites?
- Targeting: Is MRI-based targeting included, and what happens if imaging cannot be completed?
- Oversight: Who prescribes treatment, supervises delivery, and addresses concerns during the course?
- Monitoring: How are symptoms and tolerability assessed, and when would the plan be reconsidered?
- Follow-up: Who manages ongoing depression care after the scheduled course?
- Costs: What is included, what may be billed separately, and what has the insurer actually authorized?
Request the plan in writing. General assurances such as “the same as Stanford” are less useful than an explanation of the protocol and any differences.
Bring the decision back to your prescriber
A useful consultation connects the evidence to your circumstances while acknowledging uncertainty. Ask what happens if symptoms do not improve, appointments are interrupted, or treatment becomes difficult to tolerate. Confirm whom to contact if your mental health worsens during or after treatment.
Our TMS frequently asked questions can help you prepare additional practical questions. The goal is not to choose the shortest advertised course, but to understand the proposed care well enough to discuss it with a qualified prescriber.
References
- Blumberger DM et al. Effectiveness of theta burst versus high-frequency repetitive transcranial magnetic stimulation in patients with depression (THREE-D): a randomised non-inferiority trial. The Lancet, 2018. PMID 29726344
- Cole EJ et al. Stanford Neuromodulation Therapy (SNT): A Double-Blind Randomized Controlled Trial. American Journal of Psychiatry, 2022. PMID 34711062